ClinicalTrials.gg
CompletedNCT02932306Updated Oct 20, 2026Results posted

Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Participants With Acne Vulgaris

A Phase 3 interventional study of IDP-121 Lotion and IDP-121 Vehicle Lotion in Acne, sponsored by Bausch Health Americas, Inc.. Completed at 39 sites in United States. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Nov 2015, registered Oct 2016).
Updated Oct 20, 2026Posted results revisedTitle changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
820
Allocation
Randomized
Ages
9 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Acne Vulgaris by Bausch Health Companies Inc. — 1 open to participants now, 1 under way, none of them phase 3. Acne Vulgaris · Bausch Health Companies Inc..

Enrollment
3rd of 35
820 · median 247
Started
2015
with 7 others
Phase 3
13 of 36
none open now
Registered
23rd of 36
by date

Among the 36 studies in Acne Vulgaris by Bausch Health Companies Inc., this one is the 3rd largest by enrollment of the 35 interventional ones that give a count, is one of 8 that started in 2015, is one of 13 in phase 3, and was the 23rd registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

1 of the 36 studies in Acne Vulgaris by Bausch Health Companies Inc. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 9 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Acne Vulgaris by Bausch Health Companies Inc., or all of them as a file.
02

Study summary

The objective of this study was to evaluate the efficacy, safety, and tolerability of a once daily topical application of IDP-121 Lotion compared with its vehicle (IDP-121 Vehicle Lotion) in participants with moderate to severe acne vulgaris (acne) (that is, acne having an Evaluator's Global Severity Score [EGSS] of 3 [moderate] or 4 [severe]).

03

Conditions studied

  • Acne

Browse trials for

04

Who can participate

Ages eligible
9 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female at least 9 years of age and older.
  • Written and verbal must be obtained. Participants less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if participant reaches age of consent during the study they should be re-consented at the next study visit).
  • Participant must have a score of 3 (moderate) or 4 (severe) on the EGSS assessment at the screening and baseline visit

Key Exclusion Criteria:

  • Use of an drug or device within 30 days of enrollment or participation in a research study concurrent with this study.
  • Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, rosacea, gram-negative folliculitis.
  • Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive.
  • Participants with a facial beard or mustache that could interfere with the study assessments.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
820 participants (actual)

Study arms

  • Experimental
    IDP-121 Lotion

    IDP-121 lotion (tretinoin 0.05 percent \[%\]) will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.

    Drug: IDP-121 Lotion

  • Placebo comparator
    IDP-121 Vehicle Lotion

    IDP-121 lotion vehicle will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.

    Drug: IDP-121 Vehicle Lotion

Interventions

  • IDP-121 lotion will be applied as per the instructions provided by the investigational center staff.

  • DrugIDP-121 Vehicle Lotion

    IDP-121 vehicle lotion will be applied as per the instructions provided by the investigational center staff.

06

What researchers measure

Primary outcomes

  1. Absolute Change From Baseline in Mean Noninflammatory Lesion Count to Week 12

    Noninflammatory lesions were defined as follows: Open comedones (blackhead) - plugged hair follicle with dilated/open orifice, black in color; and Closed comedones (whitehead) - plugged hair follicle: small opening at skin surface. For noninflammatory facial lesions, open and closed comedones were recorded as a single count.

    Time frame: Baseline (Day 0), Week 12

  2. Absolute Change From Baseline in Mean Inflammatory Lesion Count to Week 12

    Inflammatory lesions were defined as follows: Papule - a solid, elevated lesion less than 5 millimeters (mm); and Pustule - an elevated lesion containing pus less than 5 mm. For inflammatory facial lesions, papules and pustules were recorded as a single count, while nodular lesions were counted and recorded separately.

    Time frame: Baseline, Week 12

  3. Percentage of Participants With Treatment Success at Week 12

    Treatment success was defined as at least a 2-grade reduction from Baseline in EGSS score and an EGSS score equating to "Clear" or "Almost Clear". EGSS was based on a 5-point scale ranging from 0 to 4; where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Percent Change From Baseline in Noninflammatory Lesion Count to Week 12

    Noninflammatory lesions were defined as follows: Open comedones (blackhead) - plugged hair follicle with dilated/open orifice, black in color; and Closed comedones (whitehead) - plugged hair follicle: small opening at skin surface. For noninflammatory facial lesions, open and closed comedones were recorded as a single count.

    Time frame: Baseline, Week 12

  2. Percent Change From Baseline in Inflammatory Lesion Count to Week 12

    Inflammatory lesions were defined as follows: Papule - a solid, elevated lesion less than 5 millimeters (mm); and Pustule - an elevated lesion containing pus less than 5 mm. For inflammatory facial lesions, papules and pustules were recorded as a single count, while nodular lesions were counted and recorded separately.

    Time frame: Baseline, Week 12

07

Results

Posted Jan 3, 2020

Participant flow

Participant flow — Overall Study
MilestoneIDP-121 LotionIDP-121 Vehicle Lotion
Started406414
Intent-to-treat (itt) population406414
Safety population378385
Completed338337
Not completed6877
Withdrew: Withdrawal by subject1625
Withdrew: Adverse event30
Withdrew: Pregnancy20
Withdrew: Protocol violation11
Withdrew: Noncompliance with study drug11
Withdrew: Lost to follow-up3640
Withdrew: Withdrawal by parent or guardian68
Withdrew: Lack of efficacy02
Withdrew: Worsening condition20
Withdrew: Withdrew due to burning,itching,stinging10

Outcome measures

PrimaryAbsolute Change From Baseline in Mean Noninflammatory Lesion Count to Week 12

Noninflammatory lesions were defined as follows: Open comedones (blackhead) - plugged hair follicle with dilated/open orifice, black in color; and Closed comedones (whitehead) - plugged hair follicle: small opening at skin surface. For noninflammatory facial lesions, open and closed comedones were recorded as a single count.

Time frame:
Baseline (Day 0), Week 12
Reported as:
Least squares mean · lesion count
Absolute Change From Baseline in Mean Noninflammatory Lesion Count to Week 12
lesion countIDP-121 LotionIDP-121 Vehicle Lotion
Absolute Change From Baseline in Mean Noninflammatory Lesion Count to Week 12-17.8 ± 15.18-10.6 ± 16.07
Statistical analysis
  • IDP-121 Lotion vs IDP-121 Vehicle Lotion · ANCOVA · p = <0.001 (Threshold for significance at 0.05.)
PrimaryAbsolute Change From Baseline in Mean Inflammatory Lesion Count to Week 12

Inflammatory lesions were defined as follows: Papule - a solid, elevated lesion less than 5 millimeters (mm); and Pustule - an elevated lesion containing pus less than 5 mm. For inflammatory facial lesions, papules and pustules were recorded as a single count, while nodular lesions were counted and recorded separately.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · lesion count
Absolute Change From Baseline in Mean Inflammatory Lesion Count to Week 12
lesion countIDP-121 LotionIDP-121 Vehicle Lotion
Absolute Change From Baseline in Mean Inflammatory Lesion Count to Week 12-13.1 ± 10.50-10.2 ± 10.87
Statistical analysis
  • IDP-121 Lotion vs IDP-121 Vehicle Lotion · ANCOVA · p = <0.001 (Threshold for significance at 0.05.)
PrimaryPercentage of Participants With Treatment Success at Week 12

Treatment success was defined as at least a 2-grade reduction from Baseline in EGSS score and an EGSS score equating to "Clear" or "Almost Clear". EGSS was based on a 5-point scale ranging from 0 to 4; where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.

Time frame:
Baseline, Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Success at Week 12
percentage of participantsIDP-121 LotionIDP-121 Vehicle Lotion
Percentage of Participants With Treatment Success at Week 1216.56.9
Statistical analysis
  • IDP-121 Lotion vs IDP-121 Vehicle Lotion · Regression, Logistic · p = <0.001 (Threshold for significance at 0.05.)
SecondaryPercent Change From Baseline in Noninflammatory Lesion Count to Week 12

Noninflammatory lesions were defined as follows: Open comedones (blackhead) - plugged hair follicle with dilated/open orifice, black in color; and Closed comedones (whitehead) - plugged hair follicle: small opening at skin surface. For noninflammatory facial lesions, open and closed comedones were recorded as a single count.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Noninflammatory Lesion Count to Week 12
percent changeIDP-121 LotionIDP-121 Vehicle Lotion
Percent Change From Baseline in Noninflammatory Lesion Count to Week 12-47.5 ± 41.92-27.3 ± 43.96
SecondaryPercent Change From Baseline in Inflammatory Lesion Count to Week 12

Inflammatory lesions were defined as follows: Papule - a solid, elevated lesion less than 5 millimeters (mm); and Pustule - an elevated lesion containing pus less than 5 mm. For inflammatory facial lesions, papules and pustules were recorded as a single count, while nodular lesions were counted and recorded separately.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Inflammatory Lesion Count to Week 12
percent changeIDP-121 LotionIDP-121 Vehicle Lotion
Percent Change From Baseline in Inflammatory Lesion Count to Week 12-50.9 ± 40.72-40.4 ± 42.29

Adverse events

Collected over Baseline (Day 0) up to Week 12. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDP-121 Lotion0/378 (0%)5/378 (1.3%)0/378 (0%)
IDP-121 Vehicle Lotion0/385 (0%)2/385 (0.5%)0/385 (0%)
Most frequent serious events
Most frequent serious events
EventIDP-121 LotionIDP-121 Vehicle Lotion
PregnancyPregnancy, puerperium and perinatal conditions2/2291/247
Abortion missedPregnancy, puerperium and perinatal conditions0/2291/247
AppendicitisInfections and infestations1/3780/385
Calculus uretericRenal and urinary disorders1/3780/385
AsthmaRespiratory, thoracic and mediastinal disorders1/3780/385
Alcoholic pancreatitisGastrointestinal disorders0/3781/385
Post procedural haemorrhageInjury, poisoning and procedural complications0/3781/385

Baseline characteristics

ITT analysis set included all randomized participants who received study drug.

Age, Continuous
Age, Continuous(years)IDP-121 LotionIDP-121 Vehicle LotionTotal
Mean20.3 ± 7.1520.5 ± 7.2620.4 ± 7.20
Sex: Female, Male
Sex: Female, Male(Participants)IDP-121 LotionIDP-121 Vehicle LotionTotal
Female229247476
Male177167344
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IDP-121 LotionIDP-121 Vehicle LotionTotal
Hispanic or Latino146168314
Not Hispanic or Latino260246506
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IDP-121 LotionIDP-121 Vehicle LotionTotal
American Indian or Alaska Native415
Asian202040
Native Hawaiian or Other Pacific Islander358
Black or African American7572147
White296308604
More than one race8816
Unknown or Not Reported000
Evaluator's Global Severity Score (EGSS)
Evaluator's Global Severity Score (EGSS)(Participants)IDP-121 LotionIDP-121 Vehicle LotionTotal
0 - Clear000
1 - Almost Clear000
2 - Mild000
3 - Moderate368366734
4 - Severe374885
Noninflammatory Lesion Count
Noninflammatory Lesion Count(lesion count)IDP-121 LotionIDP-121 Vehicle LotionTotal
Mean38.0 ± 15.6739.2 ± 16.7038.6 ± 16.20
Inflammatory Lesion Count
Inflammatory Lesion Count(lesion count)IDP-121 LotionIDP-121 Vehicle LotionTotal
Mean26.1 ± 5.5626.4 ± 5.6326.3 ± 5.60
08

Study locations

39 sites
  • Valeant Site 36
    Guntersville, Alabama 35976, United States
  • Valeant Site 14
    Phoenix, Arizona 85032, United States
  • Valeant Site 28
    Hot Springs, Arkansas 71913, United States
  • Valeant Site 38
    Fountain Valley, California 92708, United States
  • Valeant Site 34
    Manhattan Beach, California 90266, United States
  • Valeant Site 23
    Oceanside, California 92056, United States
  • Valeant Site 35
    Ranch Cucamonga, California 91730, United States
  • Valeant Site 20
    San Diego, California 92123, United States
  • Valeant Site 32
    Denver, Colorado 80220, United States
  • Valeant Site 10
    Shelton, Connecticut 06484, United States
  • Valeant Site 02
    Boynton Beach, Florida 33437, United States
  • Valeant Site 15
    Coral Gables, Florida 33146, United States
  • Valeant Site 37
    Miami, Florida 33142, United States
  • Valeant Site 39
    Pembroke Pines, Florida 33028, United States
  • Valeant Site 01
    West Palm Beach, Florida 33401, United States
  • Valeant Site 19
    Boise, Idaho 83704, United States
  • Valeant Site 04
    Arlington Heights, Illinois 60005, United States
  • Valeant Site 27
    Carmel, Indiana 46032, United States
  • Valeant 12
    Plainfield, Indiana 46168, United States
  • Valeant Site 09
    Louisville, Kentucky 40202, United States
  • Valeant Site 16
    Louisville, Kentucky 40217, United States
  • Valeant Site 33
    Needham, Massachusetts 02492, United States
  • Valeant Site 11
    Warren, Michigan 48088, United States
  • Valeant Site 08
    Omaha, Nebraska 68114, United States
  • Valeant Site 25
    Omaha, Nebraska 68144, United States
  • Valeant Site 13
    Berlin, New Jersey 08009, United States
  • Valeant Site 03
    Albuquerque, New Mexico 87106, United States
  • Valeant Site 26
    New York, New York 10022, United States
  • Valeant Site 31
    Stony Brook, New York 11790, United States
  • Valeant 05
    Gresham, Oregon 97030, United States
  • Valeant Site 22
    Fort Washington, Pennsylvania 19034, United States
  • Valeant Site 24
    Charleston, South Carolina 29414, United States
  • Valeant Site 06
    Dallas, Texas 75231, United States
  • Valeant Site 30
    Houston, Texas 77004, United States
  • Valeant Site 17
    Pflugerville, Texas 78660, United States
  • Valeant Site 07
    San Antonio, Texas 78229, United States
  • Valeant 18
    Webster, Texas 77598, United States
  • Valeant Site 29
    Salt Lake City, Utah 84117, United States
  • Valeant Site 21
    Norfolk, Virginia 23502, United States
09

References and documents

Publications

  • Tyring SK, Kircik L, Pariser DM, Woolery-Lloyd HC, Harper JC, Bhatt V, Pillai R, Guenin E. The Effects of Once-Daily Tretinoin 0.05% Lotion on Quality of Life in Patients with Moderate-to-Severe Acne Vulgaris. Am J Clin Dermatol. 2020 Dec;21(6):891-899. doi: 10.1007/s40257-020-00559-3. PubMed 32886337 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Feb 2017, 15 months.

Results were first posted in Jan 2020, 2 years 10 months after primary completion. A results delay was requested in Jan 2018.

Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 15 months is above that.

Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2016
First posted
Oct 13, 2016
StartActual
Nov 3, 2015
Primary completionActual
Feb 22, 2017
CompletionActual
Feb 22, 2017
Results delay requested
Jan 5, 2018
Results first posted
Jan 3, 2020
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Oct 20, 2026
Sites
1 site added, 1 site removed
Show site
  • Valeant Site 35 · Ranch Cucamonga, United States
Show 1 removed
  • Valeant Site 35 · Rancho Cucamonga, United States
Oct 20, 2026
Title
Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Participants With Acne Vulgaris
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Posted results revised
    1 site added, 1 site removed
    Show site
    • Valeant Site 35 · Ranch Cucamonga, United States
    Show 1 removed
    • Valeant Site 35 · Rancho Cucamonga, United States
    Title Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Participants With Acne Vulgaris
    + 1 other change: index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02932306
Responsible party
Sponsor
First posted
Oct 13, 2016
Start date
Nov 3, 2015
Primary completion
Feb 22, 2017
Completion
Feb 22, 2017
Results posted
Jan 3, 2020
Last update
Oct 20, 2026

Study contacts

Tim Theisen
study chair · TKL Research, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IDP-121

Start the discussion